Completed PHASE3 INTERVENTIONAL 2-arm NCT00684177

Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)

A Randomized, Double-Blind, Multicenter, Placebo-controlled, Phase III Superiority Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, Versus Placebo Ointment Applied Twice Daily for 5 Days in the Treatment of Adult and Pediatric Subjects With SITL

Sponsor: GlaxoSmithKline

Conditions Skin Infections, Bacterial

Interventions Placebo ointment Retapamulin Ointment, 1%

Updated 6 times since 2017 Last updated: Oct 11, 2016 Started: May 31, 2008 Primary completion: Oct 31, 2009 Completion: Oct 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Skin Infections, Bacterial and is currently completed. GlaxoSmithKline leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

May 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Arlington Heights, United States , Bangalore, India , Belville, South Africa , Benoni, South Africa , Bountiful, United States , Brooklyn, United States , Buenos Aires, Argentina , Butte, United States , Cape Town, South Africa and 40 more locations